BioMarin Pharmaceutical Inc.

NasdaqGS-BMRN

OverviewFinancialsInvestor RelationsResearchEstimatesNewsOwnershipIndustryDividendsModelingFilings

Operating Activities	LTM	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
Net Income	520.4	426.9	167.6	141.6	-64.1	854	-23.8	-77.2	-117	-630.2	-171.8
Net Income
Depreciation & Amortization	82.7	96.4	104.4	102	108	105.2	105.3	95.7	87.9	96.9	47.2
Depreciation and Amortization
Share-Based Compensation Expense	186.4	201.6	207.1	196.3	197.3	189.7	159.9	148.8	140.3	134.6	111.5
Stock-Based Compensation
Other Adjustments	135.8	64.4	16.7	-167.6	-2.7	-838.6	-92	-97.7	-25.9	330.8	-252.7
Non-Cash Interest Expense
Amortization of Premium (Accretion of Discount) on Investments
Imputed Interest on Acquisition Obligation
Gain on Sale of Nonfinancial Assets
Gain on Termination of Leases
Equity in the Income of BioMarin/Genzyme LLC
Gain on Sale of Equity Investment
Inventory Reserves, Net of Stock-Based Compensation
Impairment of Assets
Loss on Conversion of Convertible Promissory Note
Deferred Income Taxes
Excess Tax Benefit from Stock Option Exercises
Unrealized Foreign Exchange Loss
Non-Cash Changes in the Fair Value of Contingent Consideration
Debt Conversion Expense
Unrealized Foreign Exchange Gain
Other
Changes in Trade Receivables	-34.8	-57.9	-190.4	-82	65.6	-59	-37.9	-54.3	-25.3	-51.5	-16.4
Accounts Receivable, Net
Changes in Inventories	-133.1	-63.5	-157.1	-68.3	-35.1	-61.2	-107.6	-23.7	-96.9	-64.5	-51
Inventory
Changes in Accounts Payable	19.2	-32.2	68.9	59	15.7	-87	77.1	38.4	45.5	-53.2	90.3
Accounts Payable and Accrued Liabilities
Changes in Unearned Revenue	—	—	—	—	—	—	—	—	—	—	—
Deferred Revenue
Changes in Other Operating Activities	-64.1	-62.7	-57.9	-5.1	19.8	-17.7	-32.8	-9.8	-17.3	8.9	23.4
Advances to BioMarin/Genzyme LLC
Other Current Assets
Other Assets
Other Long-Term Liabilities
Cash from Operating Activities	914	572.8	159.3	175.9	304.5	85.4	48.3	20.2	-8.8	-227.8	-219.5
Net Cash Provided by Operating Activities

Investing Activities	LTM	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
Capital Expenditure	-81.8	-85.4	-96.7	-121	-95.6	-114.3	-145	-144.6	-199.2	-148.4	-227.7
Purchases of Property, Plant and Equipment
Proceeds from Sale of Property, Plant & Equipment	—	10	—	103.3	—	67.2	25	50	—	—	—
Proceeds from Sale of Nonfinancial Assets
Purchases of Intangible Assets	-6.3	-12	-10.9	-10.6	-23.6	-23.2	-18.4	—	—	—	-371.8
Purchase of Intangible Assets
Proceeds from Sale of Intangible Assets	—	—	—	—	—	—	—	—	125	—	410
Proceeds from Sale of Intangible Asset
Purchases of Investments	-371.1	-410.3	-868.5	-611.8	-937.1	-538.4	-632	-634.8	-655.4	-699.7	-873.2
Purchases of Investments
Investment in Equity Securities
Investment in Convertible Note
Proceeds from Sale of Investments	449.1	633	864.9	620	691	555.8	740.2	993.7	426	367.6	424.7
Maturities and Sales of Investments
Payments for Business Acquisitions	—	—	—	—	—	—	—	—	—	-2.8	-538.4
Business Acquisitions, Net of Cash Acquired
Other Investing Activities	—	1.1	—	—	-1	-0.7	-0.8	—	-1.8	-0.7	-3.3
Change in Restricted Cash
Funds Held in Escrow for the Purchase of Real Property
Investments in BioMarin/Genzyme LLC
Distributions from BioMarin/Genzyme LLC
Settlement of Dispute with Medicis
Other
Cash from Investing Activities	-295.4	136.5	-111.2	-20	-366.3	-53.6	-31	264.4	-305.5	-484	-1,179.6
Net Cash Provided by Investing Activities

Financing Activities	LTM	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
Issuance of Long-Term Debt	—	—	—	—	—	585.8	—	—	481.7	—	—
Proceeds from Equipment and Facility Loans
Proceeds from Convertible Senior Subordinated Note Offering, Net
Repayments of Long-Term Debt	—	-495	—	—	-3	-381.9	-5.1	-375	-0	—	—
Net Payment on Debt Conversion
Payments for Debt Conversion
Repayments of Convertible Debt
Repayment of Acquisition Obligation
Principal Repayments of Financing Leases
Net Issuance / (Repayments) of Long-Term Debt	—	-495	—	—	-3	203.8	-5.1	-375	481.7	—	—
Issuance of Common Shares	15.6	49.3	69.4	69.3	49.2	71.9	31.6	67.5	60.9	787.2	951.3
Proceeds from Exercises of Awards Under Equity Incentive Plans
Proceeds from Public Offering of Common Stock, Net
Repurchases of Common Shares	-58.2	-77.6	-76.3	-54.3	-45.8	-94.6	-42.7	-35.9	-33.5	-59.5	-23
Taxes Paid Related to Net Share Settlement of Equity Awards
Repurchase of Common Stock
Net Issuance / (Repurchases) of Common Shares	-42.6	-28.3	-7	15.1	3.4	-22.7	-11.1	31.6	27.4	727.7	928.3
Other Financing Activities	—	-3.2	-11.8	-33.7	-0.4	—	-58.5	-44.6	-1.9	-0.6	-2.6
Change in Cash Balances Related to Long-Term Debt
Excess Tax Benefit from Stock Option Exercises
Purchase of Capped Call Share Options
Payments of Contingent Consideration
Other
Cash from Financing Activities	-42.7	-526.4	-18.7	-18.7	-0	181.1	-74.7	-388	507.1	727.1	925.7
Net Cash Provided by (Used In) Financing Activities
Net Cash Provided by Financing Activities

Free Cash Flow	LTM	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
Free Cash Flow	832.1	487.4	62.6	54.9	209	-28.9	-96.8	-124.4	-208	-376.2	-447.2
NOPAT	471.6	362	165.2	-61.7	-70	721.5	-76.7	-162.9	-340.5	-609	-866
Levered Free Cash Flow	343.4	-215.6	29.2	108.2	-54.2	882.8	-131.9	-496.3	184.6	-790.5	-289.6
Unlevered Free Cash Flow	294.5	214.5	26.8	-95	-57.1	546.5	-179.7	-207	-520.6	-769.3	-983.7
Net Change in Cash	575.9	182.9	29.3	137.2	-61.8	212.9	-57.4	-103.4	192.9	15.2	-473.4